NCT04924647

Lenalidomide and Dexamethasone for Rosai-Dorfman Disease

Lenalidomide and Dexamethasone for Rosai-Dorfman Disease: A Single Arm, Single Center, Prospective Phase 2 Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Rosai-Dorfman Disease (RDD) is a rare, heterogeneous histiocytic disorder. Because of the rarity of RDD and a lack of prospective randomized trials, the treatment strategy for RDD is mostly based on retrospective study. Steroid was suggested as frontline treatment as RDD with only lymph nodes involvement. Studies showed thalidomide or lenalidomide showed some effect in recurrent/refractory skin RDD. The investigators want to analyze the efficacy and toxicity of lenalidomide combined with dexamethasone regimens in the treatment of RDD among adult patients at our hospital.

Conditions

• Rosai-Dorfman Disease

Interventions

Type	Name	Description
DRUG	lenalidomide and dexamethasone	lenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22

Timeline

• Start date: 2021-06-08
• Primary completion: 2023-12-31
• Completion: 2024-12-31
• First posted: 2021-06-14
• Last updated: 2021-06-16

Locations

1 site across 1 country: China